The CAD Screening You're Already Missing—And How It's Costing You

More than half of coronary artery disease patients experience a heart attack or sudden death as their first symptom — no warning, no prior diagnosis, no chance for intervention. According to a peer-reviewed review published on PubMed, that is not a rare outlier scenario. That is the modal presentation of this disease.

Coronary artery disease is the defining silent killer in primary care. It affects more than 20.5 million U.S. adults and accounts for 39.5% of all cardiovascular deaths, according to the American Heart Association's 2025 Heart Disease and Stroke Statistics Update. Most of those patients have a primary care physician. Many of them had a routine visit within the year before their event.

That visit was a missed window. And until now, Internal Medicine practices had no practical tool to close it.

This is the clinical reality — and the revenue reality — that every Internal Medicine practice decision-maker needs to confront in 2026.

Why Standard Risk Stratification Leaves CAD Hidden in Your Patient Panel

Framingham and Pooled Cohort Equation (PCE) scores were built on population averages. Your patient panel is not average — and the mismatch is costing patients their lives.

The structural problem: both tools rely heavily on symptomatic presentation and traditional risk factors. A well-controlled diabetic woman in her 50s with borderline cholesterol and no chest pain scores low-to-intermediate. She gets lifestyle counseling and a follow-up in six months. Except a 2025 peer-reviewed study published in Cureus found silent myocardial ischemia in 37.65% of diabetic patients with no prior history of overt CAD. That is not a rare edge case. That is more than one in three of your diabetic patients walking out the door with undetected ischemia.

• Atypical presentations dominate in women — fatigue, dyspnea, and jaw pain replace the textbook chest-clutching scenario that risk calculators were trained to catch
• Well-managed comorbidities mask clinical urgency — a diabetic with an A1c of 7.1% and controlled BP does not trigger alarm; the risk score agrees
• Silent ischemia leaves no paper trail — Consultant360 reports an estimated 2 to 3 million Americans with stable CAD carry silent ischemia with zero symptoms to report at a routine visit

The tools available in most IM offices — a 12-lead EKG and a risk calculator — were not designed to detect silent obstructive disease at rest. This is a tooling gap, not a clinical judgment failure. Physicians are doing exactly what their instruments allow. The instruments are simply insufficient for the patient population they are seeing.

The Downstream Cost of a Missed Diagnosis: ED Visits, Lost Revenue, and Liability Exposure

A missed CAD diagnosis does not just hurt the patient — it restructures the practice's financial reality in ways most administrators never fully account for.

When a patient suffers an acute coronary event, the care relationship fractures. They go to the ED, get admitted to cardiology, and the Internal Medicine practice loses the chronic care management revenue it had been collecting. Quality metric scores tied to value-based contracts drop. And if that patient had a documented office visit in the months prior — with no cardiac workup initiated — the liability exposure is significant.

• Lost CCM and AWV revenue — a patient absorbed into cardiology post-event rarely returns as an actively managed primary care patient
• Quality metric degradation — undetected CAD directly affects HEDIS cardiovascular measures tied to value-based bonus payments
• Malpractice exposure — a documented visit within 12 months of an acute CAD event is a plaintiff attorney's starting point

The access problem makes this worse. According to Cardiovascular Business (citing AMN Healthcare's 2025 Survey of Physician Appointment Wait Times), the average wait to see a cardiologist is now 32.7 days — a 74% increase since 2004. A referral slip is not a clinical solution. It is a 33-day window during which nothing is being done.

That gap is where the missed diagnosis becomes a financial event.

How CorVista Integrates CAD Screening Into the Internal Medicine Workflow

UnitedHealthcare's 2026 Medicare Advantage referral mandate didn't just change a billing rule — it reassigned clinical responsibility. According to Cardiovascular Business, UHC now requires a PCP referral before any cardiology specialist visit, with claim denials falling on the provider if that referral is missing. The Internal Medicine practice is now the mandatory evaluation point — not a handoff station.

The problem: most IM offices have no tool to actually evaluate those patients. A standard EKG catches arrhythmia, not ischemia. Sending the patient to cardiology means a 32.7-day average wait, per AMN Healthcare's 2025 Survey of Physician Appointment Wait Times. That is a month of clinical exposure on a condition that kills without warning.

CorVista closes that gap directly in the exam room. The system is:

• Non-invasive and resting-state — no exercise protocol, no radiation, no contrast, no fasting, no injection
• Point-of-care — results available same visit, no hospital scheduling required
• Staff-efficient — sensor placement and data acquisition add minimal clinical burden to an existing visit workflow
• High negative predictive value — 99% NPV for ruling out significant CAD, based on the IDENTIFY study (N=1,816)

Clinically, the patient visits that trigger appropriate CorVista use are exactly the ones already filling your schedule:

• Annual wellness or chronic care visits for patients with diabetes, hypertension, or metabolic syndrome
• New or worsening chest pain, dyspnea, or unexplained fatigue with low-to-intermediate pre-test probability
• Patients flagged under UHC's new referral requirement before a cardiology authorization is written

A negative CorVista result supports a documented rule-out pathway, avoiding an unnecessary specialist referral. A positive result generates a clinically substantiated cardiology referral — exactly the kind UHC's policy now requires before a claim will clear.

On the billing side, the AMA assigned CorVista CPT code 1104T, effective January 1, 2027, for augmentative AI algorithmic analysis of CAD, pulmonary hypertension, and elevated pulmonary capillary wedge pressure. Category III codes establish the utilization record that supports permanent reimbursement pathways. Practices that begin documentation now are building that record from day one.

Building the ROI Case: What CorVista Screening Yields Per Practice

The financial argument for CorVista starts with your existing patient panel — not new patients you need to recruit.

A standard Internal Medicine practice carrying 1,500–2,000 active patients will have a meaningful subset with diabetes, hypertension, dyspnea, or chest pain — all CorVista-indicated presentations. According to PMC/Diabetologia, previously unknown heart failure was found in 27.7% of older type 2 diabetes patients studied systematically. That is not a cardiology problem waiting to happen — it is a billing opportunity sitting in your chronic care schedule right now.

The revenue model has three layers:

• Direct diagnostic billing: CPT code 1104T (effective January 1, 2027) creates the formal reimbursement pathway for AI-assisted point-of-care cardiac analysis. Practices that onboard CorVista before year-end are positioned to bill from day one.
• Quality metric protection: Catching undiagnosed CAD before an acute event protects HEDIS performance scores and value-based contract bonuses — both of which erode when a high-risk patient converts to an ED admission.
• Patient retention revenue: A patient whose CAD is caught and managed in your practice stays in your care continuum. One handed off post-MI rarely returns at the same visit frequency — or at all.

The peer-reviewed cost economic analysis published in the Journal of Visualized Experiments found the CorVista System economically beneficial specifically because it reduces downstream high-cost care and prevents loss to follow-up — the exact failure mode most IM practices experience after a referral disappears into a 33-day cardiology wait.

Malpractice exposure reduction is the metric administrators rarely quantify but should. According to StatPearls, 15–30% of acute MI patients show evidence of prior silent ischemia that went undetected. A documented in-office screening study — with a traceable result — changes the liability profile of a prior patient encounter from "no workup performed" to "evaluated and triaged appropriately."

That is a defensible chart. The absence of one is not.

The Internal Medicine practice is no longer a passive checkpoint in cardiac care. Payer policy, access constraints, and diagnostic technology have converged to make it the primary decision point — whether or not the practice is equipped to act.

The American healthcare system spends over $200 billion annually on hospital care and medications related to heart disease, according to the University of Utah Cardiovascular Research & Training Institute. The bulk of that spend is downstream. It is what happens after detection fails. Practices that own the screening moment reduce their patients' contribution to that number — and capture the billing opportunity that currently evaporates when a patient deteriorates before anyone acts.

CorVista is not a device purchase. It is a clinical infrastructure decision with a reimbursement pathway attached. CPT code 1104T, effective January 1, 2027, exists. The Mayo Clinic collaboration exists. The ACC.26 data — showing strong sensitivity across sex, age, and BMI subgroups for noninvasive INOCA detection — exists. The clinical case is built.

Practices that delay are not playing it safe. They are ceding both diagnostic authority and billable encounters to health systems that are already moving faster.

• Request a CorVista workflow integration demo tailored to your practice volume and payer mix
• Download the CorVista reimbursement and CPT code reference sheet for Internal Medicine practices
• Schedule a 20-minute ROI consultation with a Perfect Rhythm practice advisor

Frequently Asked Questions

What is undiagnosed coronary artery disease in primary care?

Undiagnosed CAD in primary care refers to significant coronary artery disease that goes undetected during routine Internal Medicine visits — often because standard risk scoring tools miss atypical presentations. According to a peer-reviewed PubMed review, more than half of CAD patients experience a heart attack or sudden death as their first clinical event, with no prior warning symptoms.

How does CorVista detect CAD in an Internal Medicine office setting?

The CorVista System is a non-invasive, point-of-care device that analyzes sensor-acquired physiological signals at rest — no radiation, no contrast agents, no fasting, and no exercise required. It received FDA clearance in September 2023 and demonstrated 88% sensitivity and a 99% negative predictive value for ruling out significant CAD in the IDENTIFY study (N=1,816).

What CPT code covers CorVista cardiac screening?

The AMA granted CorVista Health Category III CPT code 1104T, effective January 1, 2027, for augmentative AI algorithmic analysis of potential CAD, pulmonary hypertension, and elevated pulmonary capillary wedge pressure. Category III codes establish the billing infrastructure and utilization data needed to pursue permanent reimbursement pathways.

Why does UnitedHealthcare's 2026 referral policy matter for Internal Medicine practices?

Effective January 1, 2026, UnitedHealthcare now requires Medicare Advantage HMO and HMO-POS patients to obtain a PCP referral before seeing a cardiologist — with claim denials for non-compliant submissions falling on the provider, not the patient. According to Cardiovascular Business, this is one of the largest referral policy shifts UHC has implemented in years, making Internal Medicine the mandatory first clinical touchpoint for cardiac evaluation.

Is CorVista appropriate for diabetic patients with no cardiac symptoms?

Yes. Silent myocardial ischemia was detected in 37.65% of diabetic patients with no prior history of overt CAD, according to a 2025 study published in Cureus. The CorVista System is specifically indicated for patients presenting with cardiovascular symptoms including chest pain, dyspnea, and fatigue — symptoms that frequently overlap with common diabetic complaints and are often under-investigated in a standard IM visit.